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        Viral infection of mammalian cells leads to trans-
activation of the IFN-     promoter, triggered by 
the recognition of viral products by cellular sen-
sors such as Toll-like receptors and the RNA 
helicases retinoic acid  –  inducible gene I (RIG-I) 
and melanoma diff  erentiation  –  associated gene 5 
(  1  ). Type I IFN release from infected cells, 
mainly IFN-     and IFN-    , plays a key role in 
innate immunity against a wide range of viruses. 
IFN establishes an antiviral state in bystander cells 
by binding to the type I IFN receptor, formed 
by the subunits IFNAR1 and IFNAR2 (  2  ). This, 
in turn, triggers the activation of the JAK  –  STAT 
signaling pathway, and the phosphorylation and 
translocation of the transcription factors STAT-1, 
STAT-2, and IFN regulatory factor (IRF) 9 to 
the nucleus, where they form a heterotrimeric 
complex designated as IFN-stimulated gene 
factor 3 (ISGF3) (  3  ). ISGF3 binds to the IFN-
stimulated response elements (ISREs) present in 
the promoters of IFN-stimulated genes (ISGs), 
leading to their induction and the activation of 
antiviral responses (  2  ). 
  It has been previously shown that one of 
the many genes induced by IFN is the tumor 
suppressor p53, because of the presence of ac-
tive ISREs in its promoter (  4  ). Widely known 
as   “  the guardian of the genome,  ”   tumor sup-
pressor p53 is activated in response to several 
types of cellular stress, including DNA dam-
age and oncogene expression. Its well-studied 
functions include inducing cell cycle arrest 
and apoptosis, which act to prevent the emer-
gence of transformed cells (  5  ). Since the fi  rst 
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  Tumor suppressor p53 is activated by several stimuli, including DNA damage and onco-
genic stress. Previous studies (Takaoka, A., S. Hayakawa, H. Yanai, D. Stoiber, H. Negishi, 
H. Kikuchi, S. Sasaki, K. Imai, T. Shibue, K. Honda, and T. Taniguchi. 2003.   Nature  . 
424:516  –  523) have shown that p53 is also induced in response to viral infections as a 
downstream transcriptional target of type I interferon (IFN) signaling. Moreover, many 
viruses, including SV40, human papillomavirus, Kaposi  ´  s sarcoma herpesvirus, adenovi-
ruses, and even RNA viruses such as polioviruses, have evolved mechanisms designated to 
abrogate p53 responses. We describe a novel p53 function in the activation of the IFN 
pathway. We observed that infected mouse and human cells with functional p53 exhibited 
markedly decreased viral replication early after infection. This early inhibition of viral 
replication was mediated both in vitro and in vivo by a p53-dependent enhancement of 
IFN signaling, specifi  cally the induction of genes containing IFN-stimulated response 
elements. Of note, p53 also contributed to an increase in IFN release from infected cells. 
We established that this p53-dependent enhancement of IFN signaling is dependent to a 
great extent on the ability of p53 to activate the transcription of IFN regulatory factor 9, 
a central component of the IFN-stimulated gene factor 3 complex. Our results demon-
strate that p53 contributes to innate immunity by enhancing IFN-dependent antiviral 
activity independent of its functions as a proapoptotic and tumor suppressor gene. 
© 2008 Muñoz-Fontela et al.  This article is distributed under the terms of an 
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the fi  rst six 
months after the publication date (see http://www.jem.org/misc/terms.shtml). 
  After six months it is available under a Creative Commons License (Attribution–
Noncommercial–Share Alike 3.0 Unported license, as described at http://creative-
commons.org/licenses/by-nc-sa/3.0/).1930 P53 ENHANCES IFN-DEPENDENT ANTIVIRAL IMMUNITY   | Mu  ñ  oz-Fontela et al. 
replication in EJp53 cells was dependent on p53 functions 
unrelated to cell cycle arrest, we used EJp16, an EJ cell line 
with a tet-regulatable p16 expression system (  16  ). As shown 
in Fig. S1 b, induced p16 expression did not interfere with 
virus replication under conditions in which these cells exhib-
ited a pattern of cell cycle arrest similar to that induced by 
p53 (Fig. S1 c). Analysis of p53 and p16 protein levels con-
fi  rmed a direct relationship between p53 expression and the 
dampening of viral replication (Fig. S1 d). 
  The type I IFN response is a major component of antivi-
ral innate immunity (  1  ). IFN establishes an antiviral state in 
bystander cells that results in the phosphorylation and/or 
translocation of the transcription factors STAT-1, STAT-2, 
and IRF9 to the nucleus, where they form a heterotrimeric 
complex termed ISGF3 (  3  ). ISGF3 binds to ISREs on the 
promoters of ISGs, leading to their induction and the activa-
tion of diff  erent antiviral mechanisms (  2  ). To test whether 
the apoptosis-independent antiviral functions of p53 were 
mediated by an eff  ect on IFN signaling, we examined whether 
p53 could up-regulate ISRE-inducible genes.   Fig.   2   a   dem-
onstrates a 10-fold higher increase in the transactivation of an 
ISRE luciferase reporter by IFN in cells containing WT p53 
compared with p53-null HCT116 cells.   To confi  rm the ef-
fects of p53 on ISRE-dependent ISGs, we examined the ex-
pression of RIG-I, MxA, and IRF7 in EJp53. As shown in 
  Fig. 2 b  , p53 expression was associated with higher basal lev-
els and enhanced activation of each of these genes in response 
to IFN treatment, as confi  rmed at the protein level for RIG-I 
(  Fig. 2 c  , top). Of note, IFN treatment also stabilized induced 
p53, which was consistent with previous reports (  7, 8  ). Basal 
transcript levels of IRF7 and Mx1 were also increased in WT 
MEFs compared with p53      /      MEFs, and their expression 
levels were preferentially increased in WT MEFs treated with 
IFN (  Fig. 2 c  , bottom). These fi  ndings suggest that basal p53 
levels are suffi   cient to induce an elevation in ISG expression 
and prime the IFN-dependent antiviral state. 
  To further investigate the contribution of p53 to the IFN 
response, we explored whether p53 expression infl  uenced the 
levels of IFN secreted by infected cells. For this purpose, we 
used Sendai virus (SeV) strain Cantell, which induces strong 
type I IFN production (  17  ). Supernatants from induced EJp53 
cells contained higher levels of IFN in response to SeV infec-
tion than uninduced cells (Fig. S2 a, available at http://www
.jem.org/cgi/content/full/jem.20080383/DC1). Pretreatment 
of Vero cells with supernatants from p53-expressing EJp53 
infected with SeV was also more eff  ective at preventing repli-
cation of recombinant Newcastle disease virus (NDV) ex-
pressing GFP (NDV-GFP), a virus that is extremely sensitive 
to IFN (Fig. S2 b) (  18  ), confi  rming the p53-dependent increase 
of IFN production in response to viral infection. 
  As p53 enhances IFN activity by increasing expression of 
ISGs, we reasoned that one or more IFN-related genes 
might be direct p53 transcriptional targets. IRF7 and IRF9 
were considered as possible candidates because of their dual 
role in IFN signaling and production (  19  –  21  ). IRF7 mRNA 
showed only a modest increase in response to p53 expression 
report that placed p53 downstream of type I IFN signaling, 
several studies have indicated that p53 is also activated indi-
rectly by type I IFN through other IFN-inducible proteins, 
such as promyelocytic leukemia protein, STAT-1, or IFIX    -1 
(  6  –  8  ). Also, it has been recently reported that cells that conserve 
p53 functions show an increase in p53-dependent apopto-
sis in response to viral infection, which is associated with 
reduced viral replication (  4, 9  ). Moreover, p53      /      mice are 
more permissive to viral infection, presumably because of 
the lack of a p53 apoptotic response (  9  ). These fi  ndings, and 
the fact that not only oncogenic viruses but also RNA vi-
ruses have evolved mechanisms designed to abrogate p53 
responses (  6  ), suggest that p53 may have a broader role in 
antiviral defense. In agreement with this hypothesis, recent 
reports established that some IFN-related genes such as IRF5 
or ISG15 are in fact p53 direct target genes, although the 
role of these interactions in antiviral defense has not yet been 
explored (  10, 11  ). 
  To further characterize the role of p53 in antiviral im-
mune response, we investigated the antiviral eff  ects of WT 
p53 in response to low viral loads, which mimic the early 
stages of infection. We report a novel mechanism of p53-
dependent enhancement of IFN signaling and production, 
both in vitro and in vivo, mediated by its transcriptional 
up-regulation of IRF9. 
    RESULTS AND DISCUSSION   
  To investigate the mechanisms by which p53 might impair 
viral replication in addition to its known proapoptotic func-
tion, we infected WT and p53      /      mouse embryo fi  broblasts 
(MEFs) with recombinant vesicular stomatitis virus (VSV) 
expressing GFP (VSV-GFP), in the presence or absence of 
a broad-spectrum caspase inhibitor (  12  ). Virus titers were 
  >  100-fold higher in the absence of p53, which was consistent 
with previous reports (  4, 9  ). However, p53 still markedly 
reduced viral replication in the presence of caspase inhibitors 
(  Fig. 1, a  –  c  ), which reduced p53-dependent cell death to lev-
els close to those observed with p53      /      MEFs (  Fig. 1 d  ).   
  To confi  rm these results, we used HCT116 colon cancer 
cells and HCT116p53      /      cells, in which p53 was inactivated 
by somatic gene targeting (  13  ). As shown in   Fig. 1 e  , early 
viral replication was greater in the absence of p53 despite the 
fact that apoptosis was not increased either in the presence or 
absence of p53 over that of uninfected cells. The inhibitory 
eff  ect of p53 on early virus replication suggested that basal 
levels of p53 are suffi   cient for the antiviral eff  ects observed. 
We performed analogous experiments with EJp53, a p53-
null bladder cancer cell with a tetracycline (tet)-regulatable 
p53 expression system (  14  ). When tet is removed from the 
culture media, p53 is up-regulated at physiological levels, and 
cell cycle arrest is induced without signifi  cant induction of 
apoptosis (  14, 15  ). We infected these cells with VSV-GFP 
and also observed signifi  cantly lower viral replication in cells 
expressing p53 (Fig. S1 a, available at http://www.jem.org/
cgi/content/full/jem.20080383/DC1), in the absence of 
apoptosis (not depicted). To confi  rm that inhibition of viral JEM VOL. 205, August 4, 2008  1931
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    Figure 1.         p53 prevents viral replication in the absence of apoptosis.   (a) Representative fl  uorescent and clear-fi  eld pictures of WT and p53     /     MEFs 
infected with VSV-GFP (MOI of 0.01 for 3 or 12 h). Immediately after infection, plates were treated or not with caspase inhibitor (20   μ  M qVD-OPH-109). 
Bars, 30   μ  m. (b) Quantitation by FACS analysis of the green fl  uorescence of cells in panel a 12 h after infection. (c) Viral titration of supernatants from 
MEFs infected with VSV-GFP for 24 h. The viral titers are represented as log (PFU/ml). (d) FACS analysis of MEFs infected with VSV for 24 h and stained 
with PI. (e) Mean fl  uorescence intensity and the percentage of Sub G  1   events (representing cell death) of PI-stained WT and p53     /     HCT116 cells infected 
with VSV-GFP for 8 h. Values in all graphs represent the mean of three biological samples, and the error bars represent standard deviations.     
(  Fig. 3 a  , top).   However, IRF9 mRNA increased with ki-
netics similar to that observed with MDM2, a known p53 
transcriptional target (  Fig. 3 a  , bottom). Neither IFNAR1 
nor IRF3 showed increased expression levels in response to 
p53 expression. The p53-dependent increase of IRF9 was also 
observed at the protein level (  Fig. 3 b  ). Finally, the   induction 1932 P53 ENHANCES IFN-DEPENDENT ANTIVIRAL IMMUNITY   | Mu  ñ  oz-Fontela et al. 
This may be explained by the elevation in the p53 protein level 
caused by IFN signaling  –  dependent p53 stabilization (  Fig. 2 c   
and   Fig. 4 b  ). Because the transactivation of ISRE-dependent 
genes and the known positive feedback of IFN production 
relies on the formation of the ISGF3 complex, in which IRF9 
plays a pivotal role (  22  ), these results help to provide a mecha-
nistic explanation for the observed p53-dependent enhance-
ment of IFN signaling and production. 
  We next performed a rescue assay by transfection of ex-
ogenous IRF9 into HCT116p53      /      cells to test whether the 
p53-dependent activation of IFN signaling was entirely attribut-
able to IRF9. As shown in   Fig. 4 d  , expression of exogenous 
IRF9 in p53      /      cells signifi  cantly increased the transactivation 
of the ISRE reporter in a dose-dependent manner (  Fig. 4 e  ). 
of IRF9 in response to viral infection, the IFN inducer Poly 
(I:C), or IFN treatment was signifi  cantly higher in the pres-
ence of p53 (  Fig. 3 c  ). 
  To assess whether IRF9 was a direct target of p53, we 
searched for p53 binding sites within the IRF9 promoter. We 
identifi  ed several putative sites (  Fig. 4 a  ) and generated a lucifer-
ase reporter construct driven by the IRF9 promoter.   As shown 
in   Fig. 4 a  , this construct strongly induced luciferase activity 
in response to either p53 or IFN. Moreover, a combination 
of both stimuli induced a synergistic response of the reporter. 
Chromatin immunoprecipitation (ChIP) analysis showed that 
the specifi  c p53 binding to region     373 in the endogenous 
IRF9 promoter was enriched in chromatin immunoprecipitates 
using a p53 antibody, especially after IFN treatment (  Fig. 4 c  ). 
    Figure 2.         p53 enhances type I IFN signaling.   (a) Levels of luciferase expression in WT and p53     /     HCT116 cells transfected with a pFOS-ISRE 
luciferase reporter (and the internal   Renilla   luciferase expression vector pRL-CMV to normalize transfection effi  ciency). 24 h after transfection, cells 
were treated or not with 500 U/ml IFN for 12 h, and luciferase intensity was then measured. Values represent the mean of three biological samples, 
and error bars represent standard deviations. (b) Real-time PCR of EJp53 cells cultured in the presence or absence of tet for 1 d and treated with 500 
U/ml IFN for 6 h. Results show RIG-I, MxA, and IRF7 mRNA expression levels in each condition compared with that of TATA binding protein (TBP; con-
trol). Results are mean values of triplicate experiments expressed as the fold difference between IFN-treated and untreated EJp53 cells. (c, top) West-
ern blots of lysates of EJp53 cultured in the presence of tet or 24 h after tet removal, and treated with 500 U/ml IFN for 24 h. (bottom) Real-time PCR 
of WT and p53     /     MEFs. Results show IRF7 and Mx1 mRNA expression levels in each condition compared with that of TBP (control). Results are mean 
values of triplicate experiments, and error bars represent standard deviations.     JEM VOL. 205, August 4, 2008  1933
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bicin, a DNA-damaging agent (  25  ), or the IRF9 reporter 
in response to IFN (Fig. S3 b). All of these results establish 
that transcriptionally active WT p53 is required to enhance 
IFN signaling. 
  Previous evidence that p53      /      mice are more sensitive 
to viral infection was attributed to the absence of p53-de-
pendent apoptosis in infected cells (  9  ). To test whether 
p53      /      mice also exhibited an impaired IFN response, we 
infected WT and p53      /      mice with SeV strain Cantell, and 
measured viral titers and IFN response in lungs. As shown 
in   Fig. 5 a  , virus was not detectable at 12 h after infection, 
but by 24 h, the viral titer was   >  100-hundred fold higher in 
mice lacking p53.   Of note, we observed a rapid increase in 
expression levels of ISGs, including IRF9, IRF7, Mx1, and 
RIG-I, in the infected lung tissue of WT mice, whereas 
this response was almost completely absent in p53      /      mice 
(  Fig. 5 b  ). These results establish that p53 enhances IFN 
antiviral immunity in vivo, as well as in vitro by promoting 
the expression of ISGs. The levels of apoptosis in infected 
lungs did not vary signifi  cantly in WT and p53      /      mice at 
these early time points, arguing further that p53-induced 
However, the maximum level achieved did not reach that 
observed in HCT116 cells expressing endogenous p53. These 
results support the conclusion that the p53-dependent tran-
scriptional activation of IRF9 contributes importantly to the 
enhancement of IFN signaling but that p53 may have other 
targets as well. 
  p53 has been reported to possess activities independent 
of its transcriptional functions (  5  ). To determine whether 
our newly identifi  ed role for p53 in enhancing IFN signaling 
also involved a nontranscriptional activity, we tested the ability 
of the p53 DNA binding domain mutants Y220C and V143A 
to enhance IFN signaling. Both of these p53 mutants occur 
frequently in human tumors, and both have been shown to 
lack p53 transcriptional activity (  23, 24  ). Both mutants failed 
to transactivate the ISRE luciferase reporter in response to 
IFN treatment (Fig. S3 a, available at http://www.jem.org/
cgi/content/full/jem.20080383/DC1) despite much higher 
levels of expression than that of endogenous WT p53, which 
strongly enhanced activation of this reporter in WT HCT116 
cells (Fig. S3 c). As controls, neither p53 mutant activated 
the p21 promoter luciferase construct in response to doxoru-
    Figure 3.         p53 enhances IRF9 expression.   (a) Real-time PCR of EJp53 cells cultured in the presence or absence of tet for 6  –  48 h. Results show IF-
NAR1, IRF3, IRF7, and IRF9 (top), and p53 and MDM2 (bottom) mRNA expression levels in each condition compared with that of TBP (control). Results 
are mean values of triplicate experiments, and error bars represent standard deviations. (b) Western blot of lysates of EJp53 cells 0  –  3 d after tet 
removal. (c) Real-time PCR of EJp53 cells cultured in the presence or absence of tet for 24 h and treated with 500 U/ml IFN, SeV (MOI of 0.1), 100 ng/ml 
Poly (I:C), or VSV-GFP (MOI of 0.01). Results show IRF9 mRNA expression levels in each condition compared with that of TBP (control). Results are mean 
values of triplicate experiments, and error bars represent standard deviations.     1934 P53 ENHANCES IFN-DEPENDENT ANTIVIRAL IMMUNITY   | Mu  ñ  oz-Fontela et al. 
    Figure 4.         IRF9 is a direct p53 target gene.   (a) Putative p53 recognition sites located in the promoter region of the IRF9 gene (open boxes; the 
    373 site is illustrated with invariant residues bolded). This genomic region was cloned into the pGL3 fi  refl  y luciferase reporter vector (IRF9-luc). 
EJp53 cells were cotransfected with either pGL3 or IRF9-luc together with a   Renilla   luciferase construct to control for transfection effi  ciency. Cells 
were cultured in the presence or absence of tet for 24 h, treated with 1,000 U/ml IFN-     for 8 h, and assessed for dual luciferase activity. Luciferase 
activity for IRF9-luc is shown relative to pGL3 basal activity. Values represent the mean of three experiments, and error bars show standard deviations. 
(b) Western blot showing p53 levels in lysates of EJp53 in the presence of tet or 24 h after tet removal. (c) p53 DNA binding activity at the IRF9 pro-
moter. EJp53 cells were cultured as described in Materials and methods, and ChIP assays were performed using an anti-p53 antibody (p53) or an JEM VOL. 205, August 4, 2008  1935
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viral infection, which would help to establish the IFN-de-
pendent antiviral state in bystander cells. This link between 
IFN signaling and production could also be caused by a p53-
mediated increase in IRF9. As part of the ISGF3 complex, 
IRF9 contributes to IFN production by inducing IRF7, which 
primes IFN release by activating IFN-     production (  19, 20  ). 
Consistent with this model, we observed a p53-dependent 
up-regulation of IRF7 in vitro and in vivo. 
  IRF5 has been previously shown to be a direct p53 target 
gene (  10  ), although there is no evidence of cross talk between 
p53 and IRF5 in antiviral defense ( 26  ). It has also been  reported 
cell death is not critical for its antiviral functions during the 
initial period after in vivo infection (unpublished data). 
  Our present studies demonstrate that p53 contributes to 
the up-regulation of ISRE-dependent genes by type I IFN 
through a mechanism involving transcriptional activation 
of IRF9 and the enhancement of IFN signaling. Moreover, 
our evidence that only WT transcriptionally active p53 was able 
to transactivate the IRF9 promoter and enhance the IFN 
activation of ISRE-dependent ISGs argues strongly against 
any nontranscriptional role. We showed further that p53 en-
hances not only IFN signaling but also IFN production after 
equivalent amount of anti  –  rabbit IgG (IgG). Real-time PCR was performed for the IRF9 promoter regions indicated, as well as the p21 promoter, which 
served as a positive control. Quantifi  cation of the amount of promoter-specifi  c immunoprecipitated DNA relative to that present in total chromatin 
was determined using the     CT method. (d) ISRE-luc reporter assay in HCT116 WT and p53     /     cells. Cells were transfected with the ISRE-luc reporter 
and treated with IFN using the conditions described in Materials and methods. In the p53     /     cells, the reporter was cotransfected with increasing 
amounts of exogenous IRF9 using the expression plasmid pCAGGs-hIRF9. Results are presented as the mean of three biological samples. The error bars 
represent standard deviations. (e) Protein levels of exogenous IRF9 in HCT116p53     /     cells.   
 
    Figure 5.         p53 enhances IFN-mediated antiviral protection in vivo.   (a) Viral titration of supernatants from the homogenized lungs of WT and 
p53     /     MEFs infected intranasally with 2   ×   10  4   PFU of SeV strain Cantell for 0  –  48 h. The viral titers are represented as log (PFU/g of tissue). (b) Real-time 
PCR of lungs of WT and p53     /     mice. Results show RIG-I, Mx1, IRF9, and IRF7 mRNA expression levels in each condition compared with that of TBP 
(control). Results are mean values of three biological samples, and error bars represent standard deviations.     1936 P53 ENHANCES IFN-DEPENDENT ANTIVIRAL IMMUNITY   | Mu  ñ  oz-Fontela et al. 
50 U/ml penicillin-streptomycin. EJp53 and EJp16 were cultured as previ-
ously described (  14, 30  ). VSV-GFP (a gift from S. Woo, Mount Sinai School 
of Medicine, New York, NY) was grown and titrated in BHK-21 cells, as 
previously described (  31  ). NDV and SeV were grown as previously de-
scribed (  18, 32  ). 
  Plasmids, antibodies, and reagents.     pHISG54-RFP/CAT (  33  ), pGL-
FOS, and pGL-FOS-ISREluc (a gift from T. Ouchi, Northwestern Uni-
versity, Evanston, IL) were transfected with FuGENE (Roche), according 
to the manufacturer  ’  s instructions. The caspase inhibitor Q-VD-OPH was 
purchased from MP Biomedicals. Universal type I IFN was purchased from 
PBL Biomedical Laboratories. Doxorubicin was purchased from Sigma-
Aldrich. Immunoblots were performed using antibodies against RIG-I 
(Prosci Inc.), p16 (BD Biosciences), p48/IRF9 (Santa Cruz Biotechnology, 
Inc.),     -tubulin (Sigma-Aldrich),     -actin (Sigma-Aldrich), and p53 (1801 
mAb; reference   15  ). To obtain the pCAGGs-hIRF9 construct, hIRF9 was 
amplifi  ed by RT-PCR from RNA obtained from human Hep-2 cells. 
Primers used for RT-PCR were 5    -CGCGGAATTCACCATGGCAT-
CAGGCAGGGCACGC-3     (hIRF9/EcoRI/5    ) and 5    -CGCGCTCGA-
GCTACACCAGGGACAGAATGGCTGC-3     (hIRF9/XhoI/3    ). The PCR 
product was cloned into the mammalian expression plasmid pCAGGs (  34  ) 
by using the restriction endonucleases EcoRI and XhoI. IRF9 expression 
was verifi  ed by sequencing and Western blotting. To generate the pEGFP-
C1-hIRF9 construct, hIRF9 was amplifi  ed from pCAGGs hIRF9 and 
cloned into the expression vector pEGFP-C1 (Clontech Laboratories, Inc.) 
by restriction endonucleases XhoI and EcoRI. GFP-IFR9 expression was 
confi  rmed by sequencing and Western blotting. The p53 Y220C and p53 
V143A point mutants were generated by site-directed mutagenesis using 
the Change-IT Multiple Mutation Site Directed Mutagenesis Kit (USB), 
according to the manufacturer  ’  s instructions. As a template, we used the 
pFLAG-p53 plasmid (a gift from J. Manfredi, Mount Sinai School of 
Medicine, New York, NY). The primers used to generate the mutants 
were 5    -GTGGTGCCCTCTGAGCCGCCTG-3     (p53YY220CFw) and 
5    -GACCTGCCCTGCGCAGCTGTGG-3     (p53V143A Fw). The pGL3-
hIRF9 promoter luciferase construct was done by using 5     RACE (Ambion) 
to sequence upstream of the transcription start site. We then cloned this 
region (    3271 bp) plus 817 bp downstream into pGL3 (Promega) using 
5    -NheI and 3    -XhoI sites. The pGL3-p21 promoter construct was previ-
ously described (  35  ). 
  FACS analysis.     Fluorescent-stained cells were transferred to polystyrene 
tubes with cell-strainer caps (BD Biosciences) and subjected to FACS (FAC-
Scan; Becton Dickinson) using CellQuest 3.2 software (Becton Dickinson) 
for acquisition and analysis. For cell-cycle analysis, cells were stained with 
propidium iodide (PI) using the CycleTEST Plus DNA reagent kit (Becton 
Dickinson), according to the manufacturer  ’  s instructions, and then subjected 
to FACS analysis. 
  Quantitative RT-PCR (qRT-PCR) analysis.     For qRT-PCR analysis, 
RNA was isolated from cells by TRI  zol   (Invitrogen) according to manufac-
turer  ’  s instructions. 100 ng RNA and SYBR green (Roche) were used in an 
ABI7900 HT instrument (Applied Biosystems), according to manufacturer  ’  s 
instructions. Table S1 (available at http://www.jem.org/cgi/content/full/
jem.20080383/DC1) shows the primers used. 
  Reporter assays.     293T cells stably expressing the pHISG54-RFP/CAT re-
porter plasmid (a gift from B. Beitzel, U.S. Army Medical Research Institute 
of Infectious Diseases, Frederick, MD) were treated with the supernatants 
indicated in each experiment to test IFN presence. RFP expression was 
visualized by epifl  uorescence. For luciferase reporter assays, cells were co-
transfected with the reporter plasmids and pRL-CMV (Promega) expressing 
  Renilla   luciferase as an internal control. 24 h after transfection, cells were 
treated with 500 U/ml IFN for 12 h more. Cell lysates were collected and 
procesed with a luciferase kit assay (Promega) according to the manufactur-
er  ’  s instructions. 
that p53 directly transactivates ISG15 (  11  ), which regulates 
several genes involved in IFN production, including PKR and 
RIG-I (  27  ). However, ISG15 has been shown to be up-regu-
lated by p53 in response to double-stranded RNA but not by 
IFN treatment or viral infection with NDV or SeV (  11  ), thus 
making ISG15 an unlikely eff  ector of the p53-dependent 
  increase in IFN production. A recent paper also indicated a 
p53-dependent stabilization of STAT-1 in response to DNA 
damage (  28  ), reinforcing the idea of a strong role for p53 in 
the induction of antiviral genes by type I IFN. These recent 
fi  ndings, and the fact that IRF9 overexpression could not 
completely restore the p53-dependent activation of the ISRE 
reporter in our rescue assays, suggest that p53 could also be 
acting to enhance IFN signaling through other IFN-related 
target genes. Therefore, further studies are necessary to deter-
mine whether p53 exerts direct control over the expression of 
other key elements of the IFN pathway. 
  A study by Dharel et al. recently reported that p53 medi-
ates inhibition of hepatitis C virus replicons through cross talk 
between p53 and IFN signaling (  29  ). The authors used a tu-
mor cell line, Huh7, harboring a Y220C p53 mutant, which 
is commonly present in human tumors with p53-inactivating 
mutations (  23, 24  ). They reported that this mutant retained 
transcriptional activity. However, this same mutant was pre-
viously shown (  23  ) and demonstrated by us to lack transcrip-
tional activity. Moreover, as shown in Fig. S3, it failed to 
activate ISRE and IRF9 reporters. Dharel et al. provided evi-
dence that p53 bound to IRF9. However, the mechanism 
linking such binding to an enhancement of the IFN response 
was reported by them to be unclear. Our studies provide 
strong evidence that the mechanism by which p53 enhances 
IFN-regulated gene expression and antiviral responses requires 
transcriptionally active p53 to up-regulate IRF9 expression and 
enhance IFN signaling. 
  Our fi  ndings indicate that p53 not only enhances apopto-
sis in response to viral infection but also plays an important 
role in the IFN-dependent antiviral response. To reconcile 
these diff  erent roles of p53 in antiviral defense, we propose a 
two-phase model. First, p53 enhances IFN production and 
signaling by contributing to a positive feedback loop through 
the transcriptional induction of IRF9 and, probably, other 
IFN-related genes. This would presumably be important in 
the early stages to counteract viral infection through the in-
duction of ISGs. In a second phase, p53 could help to thwart 
viral replication by eliminating infected cells through induc-
tion of apoptosis. Our study may also have relevance regard-
ing the clinical use of oncolytic viruses in tumor therapy. For 
example, p53 mutant tumor cells might be more permissive 
than WT cells for viral replication because of the lack of opti-
mal IFN production and signaling. Moreover, our results pro-
vide a rationale to devise therapeutic strategies that enhance 
p53 expression to control viral infections. 
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  NDV-GFP bioassay.     Supernatants from virus-infected cells were inacti-
vated for 10 min under UV light and added to fresh Vero cells. 16 h later, 
cells were infected with NDV-GFP (multiplicity of infection [MOI] of 2). 
24 h after infection, GFP expression was monitored by epifl  uorescence. As 
positive controls, we used Vero cells treated with the amounts of IFN-     
indicated in the fi  gures. 
  ChIP assay.     ChIP assays were performed according to the manufacturer  ’  s in-
struction, using the ChIP assay kit (Millipore). ChIP DNA extracted from the 
cell lysates was next used as a template for PCR. 
  In vivo viral infections.     WT and p53-null mice of a C57BL/6 pure back-
ground (B6;129-  Trp53  tm1Brd    ; Taconic) (  36  ) were infected by applying the vi-
rus (2   ×   10  4   PFU of SeV strain Cantell diluted in PBS) directly to the nostrils. 
Lungs were extracted and homogenized mechanically in a PBS solution. 
  Supernatants were used to titrate SeV in 293T HISG54-RFP/CAT by count-
ing red fl  uorescent cells in serial dilutions of such supernatants. Pellets were 
used for qRT-PCR. All animal protocols were approved by the Institutional 
Animal Care and Use Committee of the Mount Sinai School of Medicine. 
  Online supplemental material.     Fig. S1 shows a p53-dependent antivi-
ral eff  ect in the EJp53-inducible cell line. As shown by comparison with 
EJp16 cells, the p53-dependent antiviral eff  ect is not caused by its ability 
to trigger cell cycle arrest. Fig. S2 shows that p53 also induces IFN pro-
duction in response to viral infection. Fig. S3 shows a lack of activation of 
the ISRE reporter by the p53 point mutants Y220C and V143A compared 
with WT p53. Neither of these mutants was also able to transactivate the 
p21 promoter and IRF9 promoter reporter constructs, indicating a lack of 
transcriptional activity. Table S1 shows primers used in qRT-PCR. Online 
supplemental material is available at http://www.jem.org/cgi/content/full/
jem.20080383/DC1. 
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